|
|
 | |||||||||||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
Background Adrenomyeloneuropathy is an X-linked recessive disorder characterized by myelopathy, peripheral neuropathy, and cerebral demyelination, which develop in association with the accumulation of very-long-chain fatty acids. The administration of oleic and erucic acids inhibits the synthesis of very-long-chain fatty acids. Recently such dietary treatment has been widely publicized as a possible cure for this disease.
Methods We conducted an open trial in 14 men with adrenomyeloneuropathy, 5 symptomatic heterozygous women, and 5 boys (mean age, 13 years) with preclinical adrenomyeloneuropathy. The patients ate a low-fat diet and received daily doses of glycerol trioleate oil (1.7 g per kilogram of body weight) and glycerol trierucate oil (0.3 g per kilogram). Clinical manifestations, cerebral and spinal cord magnetic resonance imaging (MRI) scans, nerve conduction, and brain-stem auditory and somatosensory evoked potentials were studied prospectively over 18 to 48 months. Plasma levels of very-long-chain fatty acids and the side effects of erucic acid were monitored monthly.
Results By week 10, plasma very-long-chain fatty acid levels declined nearly to normal. Nonetheless, over a mean follow-up of 33 months none of the 14 men with adrenomyeloneuropathy improved. In nine men there was functional deterioration, coincident in four with new cerebral lesions on MRI. In a single patient there was a reduction in cerebellar demyelination, but without clinical improvement. In one of the five asymptomatic boys signs of myelopathy developed. There were no changes in the symptomatic heterozygous women. There was some improvement in peroneal-nerve conduction, but no detectable clinical improvement. Conduction to the parietal cortex (T12-P37 interpeak latency) worsened in both the symptomatic men and the boys with preclinical adrenomyeloneuropathy. There was no change in other somatosensory evoked potentials or in brain-stem auditory evoked potentials. Asymptomatic thrombocytopenia (<100,000 cells per cubic millimeter) was noted in six patients.
Conclusions In this open trial we found no evidence of a clinically relevant benefit from dietary treatment with oleic and erucic acids ("Lorenzo's Oil") in patients with adrenomyeloneuropathy. .
Source Information
From INSERM Unite 342 (P.A., F.R., N.C.) and the Departments of Radiology (C.A.), Neurology (I.J., A.L.), and Pediatric Endocrinology (C.J., P.-F.B.), Hopital St. Vincent de Paul; and the Departments of Neurophysiology (M.-C.L.-R., F.B.), and Biochemistry (C.W.), Hopital St. Antoine -- both in Paris.
Address reprint requests to Dr. Aubourg at INSERM U342, Hopital St. Vincent de Paul, 82 Ave. Denfert-Rochereau, 75014 Paris, France.
Related Letters:
More on Lorenzo's Oil
Odone A., Odone M., Aubourg P., Rizzo W. B.
Extract |
Full Text
N Engl J Med 1994;
330:1904-1905, Jun 30, 1994.
Correspondence
Lorenzo's Oil and Lymphocytopenia
Unkrig C. J., Schroder R., Scharf R. E., Aubourg P.
Extract |
Full Text
N Engl J Med 1994;
330:577, Feb 24, 1994.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |
